# Novel Psychiatric Therapeutics Domain: Neuroscience & Brain-Computer Interfaces · 359 papers indexed · newest 2026-10-26 Psychedelic-assisted therapy, muscarinic antipsychotics, neurosteroids, rapid-acting antidepressants and accelerated neuromodulation. Key concepts: depression, psychedelic ## Most influential - **[Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial](https://space-kitty.com/papers/doi:10.1177/0269881116675513)**. Roland R. Griffiths, Matthew W. Johnson, Michael Anthony Carducci et al. · 2016 · Journal of Psychopharmacology (doi:10.1177/0269881116675513 · 2,200 citations). Source: > Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up… > _Abstract excerpt by Roland R. Griffiths et al., CC-BY, https://doi.org/10.1177/0269881116675513; truncated._ - **[Trial of Psilocybin versus Escitalopram for Depression](https://space-kitty.com/papers/doi:10.1056/nejmoa2032994)**. Robin Lester Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al. · 2021 · New England Journal of Medicine (doi:10.1056/nejmoa2032994 · 1,390 citations). Source: - **[Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial](https://space-kitty.com/papers/doi:10.1177/0269881116675512)**. Stephen Ross, Anthony P. Bossis, Jeffrey R. Guss et al. · 2016 · Journal of Psychopharmacology (doi:10.1177/0269881116675512 · 1,697 citations). Source: > BACKGROUND: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. METHODS: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin, both in conjunction with psychotherapy. The primary outcomes were anxiety and depression assessed between groups … > _Abstract excerpt by Stephen Ross et al., CC-BY, https://doi.org/10.1177/0269881116675512; truncated._ - **[Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression](https://space-kitty.com/papers/doi:10.1056/nejmoa2206443)**. Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez et al. · 2022 · New England Journal of Medicine (doi:10.1056/nejmoa2206443 · 1,166 citations). Source: - **[Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study](https://space-kitty.com/papers/doi:10.1016/s2215-0366(16)30065-7)**. Robin Lester Carhart-Harris, Mark Bolstridge, James Rucker et al. · 2016 · The Lancet Psychiatry (doi:10.1016/s2215-0366(16)30065-7 · 1,538 citations). Source: > BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression. METHODS: In this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resis… > _Abstract excerpt by Robin Lester Carhart-Harris et al., CC-BY, https://doi.org/10.1016/s2215-0366(16)30065-7; truncated._ - **[Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder](https://space-kitty.com/papers/doi:10.1001/jamapsychiatry.2020.3285)**. Alan K. Davis, Frederick Streeter Barrett, Darrick G. May et al. · 2020 · JAMA Psychiatry (doi:10.1001/jamapsychiatry.2020.3285 · 1,300 citations). Source: > Importance: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. Objective: To investigate the effect of psilocybin therapy in patients with MDD. Design, Setting, and Participants: This randomized, waiting list-controlled clinical trial was conducted at the Center for Psychedelic and Consciousness Research at Johns … > _Abstract excerpt by Alan K. Davis et al., CC-BY, https://doi.org/10.1001/jamapsychiatry.2020.3285; truncated._ - **[Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer](https://space-kitty.com/papers/doi:10.1001/archgenpsychiatry.2010.116)**. Charles S. Grob, Alicia L. Danforth, Gurpreet S Chopra et al. · 2010 · Archives of General Psychiatry (doi:10.1001/archgenpsychiatry.2010.116 · 1,205 citations). Source: - **[Psilocybin with psychological support for treatment-resistant depression: six-month follow-up](https://space-kitty.com/papers/doi:10.1007/s00213-017-4771-x)**. Robin Lester Carhart-Harris, Mark Bolstridge, Camilla Day et al. · 2017 · Psychopharmacology (doi:10.1007/s00213-017-4771-x · 970 citations). Source: > RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as t… > _Abstract excerpt by Robin Lester Carhart-Harris et al., CC-BY, https://doi.org/10.1007/s00213-017-4771-x; truncated._ - **[Single-Dose Psilocybin Treatment for Major Depressive Disorder](https://space-kitty.com/papers/doi:10.1001/jama.2023.14530)**. Charles L. Raison, Gerard Sanacora, Joshua D. Woolley et al. · 2023 · JAMA (doi:10.1001/jama.2023.14530 · 544 citations). Source: - **[REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics](https://space-kitty.com/papers/doi:10.1124/pr.118.017160)**. Carhart-Harris RL, Friston KJ · 2019 · Pharmacological reviews (doi:10.1124/pr.118.017160 · 711 citations). Source: > This paper formulates the action of psychedelics by integrating the free-energy principle and entropic brain hypothesis. We call this formulation relaxed beliefs under psychedelics (REBUS) and the anarchic brain, founded on the principle that-via their entropic effect on spontaneous cortical activity-psychedelics work to relax the precision of high-level priors or beliefs, thereby liberating bottom-up information flow, particularly via intrinsic sources such as the limbic system. We assemble evidence for this model and show how it can explain a broad range of phenomena associated with the psyc… > _Abstract excerpt by Carhart-Harris RL et al., CC-BY, https://doi.org/10.1124/pr.118.017160; truncated._ - **[Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression](https://space-kitty.com/papers/doi:10.3389/fphar.2017.00974)**. Leor Roseman, David Nutt, Robin Lester Carhart-Harris · 2018 · Frontiers in Pharmacology (doi:10.3389/fphar.2017.00974 · 808 citations). Source: > Introduction: It is a basic principle of the ‘psychedelic’ treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) (sharing features with mystical-type experience) and Dread of Ego Dissolution (DED) (similar to anxiety) would predict long-term positive outcomes, whereas sensory perceptual effects… > _Abstract excerpt by Leor Roseman et al., CC-BY, https://doi.org/10.3389/fphar.2017.00974; truncated._ - **[The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs](https://space-kitty.com/papers/doi:10.3389/fnhum.2014.00020)**. Carhart-Harris RL, Leech R, Hellyer PJ et al. · 2014 · Frontiers in human neuroscience (doi:10.3389/fnhum.2014.00020 · 716 citations). Source: > Entropy is a dimensionless quantity that is used for measuring uncertainty about the state of a system but it can also imply physical qualities, where high entropy is synonymous with high disorder. Entropy is applied here in the context of states of consciousness and their associated neurodynamics, with a particular focus on the psychedelic state. The psychedelic state is considered an exemplar of a primitive or primary state of consciousness that preceded the development of modern, adult, human, normal waking consciousness. Based on neuroimaging data with psilocybin, a classic psychedelic dru… > _Abstract excerpt by Carhart-Harris RL et al., CC-BY, https://doi.org/10.3389/fnhum.2014.00020; truncated._ - **[Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial](https://space-kitty.com/papers/doi:10.1001/jamapsychiatry.2022.2096)**. Bogenschutz MP, Ross S, Bhatt S et al. · 2022 · JAMA psychiatry (doi:10.1001/jamapsychiatry.2022.2096 · 504 citations). Source: > Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and psychotherapy. Design, setting, and participants In this double-blind randomized clinical trial, participants were offered 12 weeks of manualized psychotherapy and were randomly assigned to receive psilocybin… > _Abstract excerpt by Bogenschutz MP et al., CC-BY, https://doi.org/10.1001/jamapsychiatry.2022.2096; truncated._ - **[Psychedelics and Psychedelic-Assisted Psychotherapy](https://space-kitty.com/papers/doi:10.1176/appi.ajp.2019.19010035)**. Collin M. Reiff, Elon E. Richman, Charles B. Nemeroff et al. · 2020 · American Journal of Psychiatry (doi:10.1176/appi.ajp.2019.19010035 · 649 citations). Source: - **[The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future](https://space-kitty.com/papers/doi:10.1038/npp.2017.84)**. Robin Lester Carhart-Harris, Guy M. Goodwin · 2017 · Neuropsychopharmacology (doi:10.1038/npp.2017.84 · 703 citations). Source: ## Newest - **[Psilocybin for Depression in Veterans](https://space-kitty.com/papers/nct:NCT07895134)**. VA Office of Research and Development · 2026 · ClinicalTrials.gov (NCT07895134). Source: - **[Analysis of Biomarkers from Visual Explorations in Individuals Suspected to Be in the Prodromal Phase of Parkinson's Disease](https://space-kitty.com/papers/arxiv:2610.34524)**. Maria F. Alcala-Durand, J. Camilo Puerta-Acevedo, Valle Pérez del Olmo et al. · 2026 (arXiv:2610.34524). Source: - **[Right putaminal gray matter change tracks psychomotor recovery after accelerated iTBS in melancholic treatment-resistant depression](https://space-kitty.com/papers/doi:10.1016/j.jad.2026.122652)**. Mao D, Wu GR, Cavendish BA et al. · 2026 · Journal of affective disorders (doi:10.1016/j.jad.2026.122652). Source: - **[Psilocybin for anhedonia in unipolar and bipolar depression: A systematic review of clinical and preclinical evidence](https://space-kitty.com/papers/doi:10.1016/j.jpsychires.2026.10.023)**. Kaczmarek ES, Wong S, Chisamore N et al. · 2026 · Journal of psychiatric research (doi:10.1016/j.jpsychires.2026.10.023). Source: - **[Awakening as a Trait-Level Transformation of Consciousness](https://space-kitty.com/papers/arxiv:2610.20856)**. Riku Ihalainen, Victor Oswald, Gulshan Kumar et al. · 2026 (arXiv:2610.20856). Source: - **[Perceptions and Attitudes Regarding Postpartum Depression on Reddit: Inductive Content Analysis](https://space-kitty.com/papers/doi:10.2196/105765)**. Srivastava A, Mawlawi F, Nelson A · 2026 · Online journal of public health informatics (doi:10.2196/105765). Source: - **[Sex differences in response to neurosteroid therapy after preterm birth](https://space-kitty.com/papers/doi:10.1016/j.yfrne.2026.101289)**. Hirst JJ, Palliser HK, Glover R et al. · 2026 · Frontiers in neuroendocrinology (doi:10.1016/j.yfrne.2026.101289). Source: - **[Energy, Information, and the Limits of Neuropsychiatric Classification](https://space-kitty.com/papers/arxiv:2610.14095)**. Farbod Khodadadi, Mina Kheirkhah, Bita Shariatpanahi et al. · 2026 (arXiv:2610.14095). Source: - **[Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment](https://space-kitty.com/papers/doi:10.1186/s12910-026-01637-7)**. Kind A, Görke J, Smirr H et al. · 2026 · BMC medical ethics (doi:10.1186/s12910-026-01637-7). Source: - **[Language-model ratings of depression reflect the rater more than the patient](https://space-kitty.com/papers/arxiv:2610.08501)**. Baihan Lin · 2026 (arXiv:2610.08501). Source: ## Clinical trials - **[Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure](https://space-kitty.com/papers/nct:NCT05603104)**. Dr. Inge Winter · 2022 · ClinicalTrials.gov (NCT05603104). Source: - **[Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia](https://space-kitty.com/papers/nct:NCT07686263)**. Karuna Therapeutics, Inc., a Bristol Myers Squibb company · 2026 · ClinicalTrials.gov (NCT07686263). Source: - **[A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression](https://space-kitty.com/papers/nct:NCT02782104)**. Janssen Research & Development, LLC · 2016 · ClinicalTrials.gov (NCT02782104). Source: - **[A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression](https://space-kitty.com/papers/nct:NCT02497287)**. Janssen Research & Development, LLC · 2015 · ClinicalTrials.gov (NCT02497287). Source: - **[Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD](https://space-kitty.com/papers/nct:NCT05711940)**. COMPASS Pathways · 2023 · ClinicalTrials.gov (NCT05711940). Source: - **[A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents](https://space-kitty.com/papers/nct:NCT07424404)**. Karuna Therapeutics, Inc., a Bristol Myers Squibb company · 2026 · ClinicalTrials.gov (NCT07424404). Source: - **[A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression](https://space-kitty.com/papers/nct:NCT02493868)**. Janssen Research & Development, LLC · 2015 · ClinicalTrials.gov (NCT02493868). Source: - **[A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder](https://space-kitty.com/papers/nct:NCT04338321)**. Janssen-Cilag International NV · 2020 · ClinicalTrials.gov (NCT04338321). Source: --- Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.